("Skip") Cummins , Cyberonics' Chairman and Chief Executive Officer, will make
the presentation.com/webcast/strh13 /cybx/ or
by going to http://www. The
replay of the webcast will be available for 90 days following the
presentation.

ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc. The VNS Therapy System is also
approved for sale as a treatment for epilepsy in all the European Economic
Area , Canada, Australia and other markets." As part of FDA's approval order, Cyberonics is
required to conduct a 450-patient post-market dosing study and a
1,000-patient, five-year patient outcome registry .
VNS Therapy is at various levels of investigational clinical study as a
potential treatment for anxiety disorders, Alzheimer's disease, chronic
headache/migraine and bulimia.

shopping health

Presentation and Audio Webcast Available On-Line

HOUSTON, Cyberonics, Inc. Robert P. Epilepsy is the second most prevalent
neurological disorder. The Cyberonics VNS Therapy System was approved by the
FDA on July 16, 1997 for use as an adjunctive therapy in reducing the
frequency of seizures in adults and adolescents over 12 years of age with
partial onset seizures that are refractory to antiepileptic medications. The VNS Therapy
System is approved for sale in the European Economic Area and in Canada as a
treatment for depression in patients with treatment -resistant or treatment-
intolerant major depressive episodes, including unipolar depression and
bipolar disorder (manic depression).cyberonics. (Nasdaq: CYBX)
today announced that Robert P. The VNS
Therapy System delivers preprogrammed intermittent mild electrical pulses to
the vagus nerve in the patient 's neck 24 hours a day. The Company's initial
market was epilepsy, a disorder characterized by recurrent seizures.cyberonics.com or
http://www. For additional information please
visit us at http://www .

conditions migraine

wsw.
Stimulation is delivered by the VNS Therapy System, an implantable generator
similar to a cardiac pacemaker. The VNS Therapy System delivers preprogrammed
intermittent mild electrical pulses to the vagus nerve in the patient's neck
24 hours a day. The Company is
headquartered in Houston , Texas and has an office in Brussels, Belgium.com . Westbrook, Vice President, Finance and
Administration and Chief Financial Officer, will be participating in the Piper
Jaffray New York Medtech Summit at the Essex House Hotel in New York City on
December 2, 2005.
The VNS Therapy System was approved by the FDA on July 15, 2005 "as an
adjunctive long-term treatment for chronic or recurrent depression for
patients 18 years of age and older who are experiencing a major depressive
episode and have not had an adequate response to four or more adequate
antidepressant treatments.

health diseases

Cyberonics Presenting at SunTrust Robinson Humphrey's 34th Annual Institutional Conference on Tuesday April 12 2005

com beginning Monday, April 11,
2005 at 8:00 AM EDT. VNS Therapy is at various levels of
investigational clinical study as a potential treatment for anxiety disorders,
Alzheimer's disease, chronic headache /migraine and bulimia. Presentation slides are now available on line at
http://www. (Nasdaq: CYBX ) was founded in 1987 to design, develop and
market medical devices for the long-term treatment of epilepsy, depression and
other chronic treatment-resistant disorders using a unique therapy, vagus
nerve stimulation (VNS). Epilepsy
is the second most prevalent neurological disorder.vnstherapy . The Company is headquartered in Houston, Texas
and has an office in Brussels, Belgium.

health conditions

Presentation slides for the SunTrust Robinson Humphrey conference will be
available on-line at http://www. SunTrust Robinson Humphrey will host a webcast of the
presentation live and by replay at http://www. was founded in 1987 to design, develop and market medical
devices for the long-term treatment of epilepsy, depression and other chronic
neurological disorders using a unique therapy, vagus nerve stimulation (VNS).

Cyberonics Participating in Piper Jaffray New York Medtech Summit on December 2 2005; Slide Presentation Now Available On Line

HOUSTON, Cyberonics, Inc. ("Skip") Cummins, Cyberonics' Chairman and
Chief Executive Officer, and Pamela B. The Cyberonics VNS
Therapy System was approved by the FDA on July 16, 1997 for use as an
adjunctive therapy in reducing the frequency of seizures in adults and
adolescents over 12 years of age with partial onset seizures that are
refractory to antiepileptic medications .com or call 1-877-NOW 4 VNS.

headache migraine

(Nasdaq: CYBX)
today announced that senior management will be presenting at the SunTrust
Robinson Humphrey 34th Annual Institutional Conference on Tuesday, April 12,
2005 at 2:40 PM EDT at The Ritz Carlton Buckhead in Atlanta.

com .cyberonics.com .

headache shopping

cyberonics. Access to the webcast and webcast replay are not protected by a
password.

ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc. Stimulation is delivered by the VNS Therapy
System(TM), an implantable generator similar to a cardiac pacemaker.

diseases health

cyberonics.com and clicking on the link for this webcast. The Company's initial market is epilepsy, a disorder
characterized by recurrent seizures . The
VNS Therapy System is also approved for sale as a treatment for epilepsy in
all the member countries of the European Economic Area, Canada, Australia and
other markets. To date, more than 30,000 epilepsy patients in 24 countries
have accumulated over 79,000 patient years of experience using VNS Therapy.
The VNS Therapy System was deemed approvable in writing by the FDA on February
2, 2005 as an adjunctive treatment for chronic treatment-resistant depression
for adults over the age of 18. According to FDA's approvable letter, final
approval was conditional on final labeling , final protocols for a post-
approval dosing optimization study and patient registry, satisfactory
compliance with the Quality System Regulations (QSR) and satisfactory
resolution of any outstanding bioresearch monitoring issues. For
additional information please visit us at http://www.cyberonics . To date, more than 32,000 epilepsy
patients in 24 countries have accumulated over 94,000 patient years of
experience using VNS Therapy. For more information on
VNS Therapy for treatment-resistant depression, including the
contraindications, warnings and precautions, see the Physician's and Patient 's
Manuals and other information at http://www.
The VNS Therapy System has been approved for sale in the European Economic
Area and in Canada as a treatment for depression in patients with
treatment -resistant or treatment-intolerant major depressive episodes,
including unipolar depression and bipolar disorder (manic depression) since
2001.